News room

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Egetis in the media

Redeye research, April 30, 2020

Egetis: Aladote upside

World of Gastrointestinal Oncology, Feb 17 2020

Neuropathy experienced by colorectal cancer patients receiving oxaliplatin

Interview with Mr Akschuti, analyst at Pareto Securities, Feb 6 2020

Pareto Securities equity analyst elaborates on the US clinical hold for the POLAR-M study.

Läkemedelsvärlden, December 14, 2020 (in Swedish)

Increasing number of cases with acetaminophen overdose in Sweden.

The independent financial news site EFN, Dec 9 2019

Egetis mentioned on EFN as one of the Swedish healthcare companies to keep an eye on. The discussion in English starts 5 min 30 sec into the program.

Liver Research

“Thus, if efficacy in high overdose patients can be established, calmangafodipir may be a promising complementary antidote to NAC.” Oct 2019

Jaeschke H, Duan L, Nguyen N, Ramachandran A, Mitochondrial damage and biogenesis in acetaminophen-induced liver injury, Liver Research

Svd Näringsliv 19 januari 2019 (in Swedish)

Egetis: Håller nerverna i styr genom studietider
Keeps their nerves in control through the study

Calendar and upcoming reports

December 14, 2023
DNB Nordic Healthcare Conference

December 19, 2023
Egetis Investor Day

Show more events



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10